MS and Demyelinating Disorders

May news includes ground-breaking FDA approvals, predictions of Alzheimer disease, and a possible biomarker for mild traumatic brain injury.

Research includes impact of body weight on migraine risk, effect of sleep on MS relapse, and side effects of statins in stroke survivors.

The four top-scoring MS abstracts submitted for AAN 2017 included 6-year outcomes with alemtuzumab treatment and pediatric MS environmental risk factors.

April news includes tools to manage brain injury and predict recovery, new drug hits and misses, and an updated epilepsy classification system.

March news includes possible brain tumor therapies, a study exploring mechanisms underlying demyelination-induced seizures, and VNS post stroke.

Studies also include stem cell transplantation for treatment-refractory MS and aspirin use for headache to lessen the need for rescue medication.

Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.

Ten general and disease-specific apps for neurologists include assessment scales, anatomical diagrams, and interactive clinical decision support.

February news includes stroke risk with Alzheimer disease & migraine, neonatal hemorrhagic stroke, and head trauma in sports.

Three new studies explore preventing secondary stroke, a potential biomarker for MS prediction, and a link between vitamin D and headache.

January news includes the first FDA-approved drug for spinal muscular atrophy, various epilepsy treatments & vitamin D’s impact on Alzheimer & headache.

Research from AES 2016 explored relationships between epilepsy and other neurological disorders, including Alzheimer disease, MS, stroke, and autism.

November news includes the first human clinical trial focusing on tau in Alzheimer disease and Zika-related microcephaly not presenting at birth.

November news includes potential Alzheimer treatments, FDA approval of a device to prevent recurrent stroke, & a newly typified headache disorder.

Studies include a potential test for MS, a link between headaches and hypothyroidism, and a risk prediction scale for stroke patients.

Data blitz presentations at ANA 2016 featured studies on neuronal dysfunction and degeneration in ALS, Parkinson disease, transverse myelitis, & more.

Award-winning posters presented during the American Neurological Association Annual Meeting discussed risks in stroke, MS, and migraine.

Oct. news includes an approved deep brain stimulation system for movement disorders & biomarkers that improve risk assessment in atrial fibrillation.

Three new multiple sclerosis studies show the promise of two drugs, amiselimod and alemtuzumab, as treatments and one, arbaclofen, for spasticity.

Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.

This ECTRIMS session includes studies using 7T and 3T MRI images and translocator protein PET scans, as well as phenotypes in gray matter and more.

Research presented at this ECTRIMS session covered management of multiple sclerosis-related fatigue, cognitive issues, and gait impairment.

Hot Topics session at ECTRIMS 2016: treat early active RRMS with potent induction therapy or immunomodulation then escalation? Where do you stand?

The session featured a study comparing MRI criteria for diagnosing MS, the role of spinal cord volume loss in predicting disease activity, and more.

New research covers treating MS early, identifying those at risk for AED-induced psychosis, & selecting a drug for epilepsy patients with migraines.

Our August news includes a potential classification system for Alzheimer disease, new findings in a 3D model of TBI, and migraine treatments.

Our July news includes the Alzheimer-diabetes link, increased rates of Parkinson, and guidelines for acute migraine treatment in the ED.

How do you approach the management of patients with multiple sclerosis and another autoimmune condition, such as psoriasis?

Our May news includes memory replay disruption in Alzheimer disease, impulse control disorder in Parkinson disease, and return to play in TBI.

From no evidence of disease activity in MS to studies of a new treatment for periodic paralysis, AAN 2016 featured many exciting clinical trials.